Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials

References

• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.
   PubMed Web of Science ®Google Scholar
• Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–485.
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Beroukhim K, Danesh MJ, et al. The psychosocial impact of acne, vitiligo, and psoriasis: a review. Clin Cosmet Investig Dermatol. 2016;9:383–392.
   PubMed Web of Science ®Google Scholar
• Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies. J Clin Aesthet Dermatol. 2010;3(4):24–38.
   PubMedGoogle Scholar
• Yin NC, McMichael AJ. Acne in patients with skin of color: practical management. Am J Clin Dermatol. 2014;15(1):7–16.
   PubMed Web of Science ®Google Scholar
• Nguyen HL, Yiannias JA. Contact dermatitis to medications and skin products. Clin Rev Allergy Immunol. 2019;56(1):41–59.
   PubMed Web of Science ®Google Scholar
• Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293–304.
   PubMed Web of Science ®Google Scholar
• Kircik LH, Draelos ZD, Berson DS. Polymeric emulsion technology applied to tretinoin. J Drugs Dermatol. 2019;18(4):s148–s154.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [Internet]. Assessing the irritation and sensitization potential of transdermal and topical delivery systems for ANDAs: guidance for industry. Silver Spring (MD): FDA; 2018. [cited 2021 Feb 8]. Available from: https://www.fda.gov/media/117569/download
   Google Scholar
• Dreno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010;49(4):448–456.
   PubMed Web of Science ®Google Scholar
• Dikicier BS. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7):2987–2992.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2019;26:1–8.
   PubMedGoogle Scholar
• Tanghetti EA, Kircik LH, Green LJ, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542–548.
   PubMed Web of Science ®Google Scholar
• Tanghetti E, Werschler WP, Lain E, et al. Novel polymeric lotion formulation of once-daily tazarotene (0.045%) for moderate-to-severe acne: pooled phase 3 analysis. J Drugs Dermatol. 2020;19(3):272–279.
   PubMed Web of Science ®Google Scholar
• Jordan WP. 24-, 48-, and 48/48-hour patch tests. Contact Dermatitis. 1980;6(2):151–152.
   PubMed Web of Science ®Google Scholar
• Berger RS, Bowman JP. A reappraisal of the 21-day cumulative irritation test in man. Cutan Ocul Toxicol. 1982;1(2):109–115.
   Web of Science ®Google Scholar
• Tanghetti EA, Werschler WP, Lain T, et al. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70–77.
   PubMed Web of Science ®Google Scholar
• Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549–558.
   PubMed Web of Science ®Google Scholar
• Foti C, Romita P, Borghi A, et al. Contact dermatitis to topical acne drugs: a review of the literature. Dermatol Ther. 2015;28(5):323–329.
   PubMed Web of Science ®Google Scholar
• Hoffman LK, Bhatia N, Zeichner J, et al. Topical vehicle formulations in the treatment of acne. J Drugs Dermatol. 2018;17(6):s6–s10.
   PubMedGoogle Scholar
• Draelos Z, Tanghetti E. A comparative clinical demonstration of the spreadability of tazarotene lotion 0.045% versus trifarotene cream 0.005%. J Skin. 2020;4(6):s113.
   Google Scholar
• Berg JE, Bowman JP, Saenz AB. Cumulative irritation potential and contact sensitization potential of tazarotene foam 0.1% in 2 phase 1 patch studies. Cutis. 2012;90(4):206–211.
   PubMed Web of Science ®Google Scholar
• Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000;43(2):S31–S35.
   PubMed Web of Science ®Google Scholar
• Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3(6):641–651.
   PubMedGoogle Scholar
• Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis. 2003;72(1):76–81.
   PubMed Web of Science ®Google Scholar
• Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. Cutis. 2005;75(5):289–293.
   PubMed Web of Science ®Google Scholar
• Millikan LE. Pivotal clinical trials of adapalene in the treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(3):19–22.
   PubMedGoogle Scholar
• Tyring SK, Kircik LH, Pariser DM, et al. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084–1091.
   PubMed Web of Science ®Google Scholar
• Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 mcg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699.
   PubMed Web of Science ®Google Scholar
• Kolli SS, Pecone D, Pona A, et al. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345–365.
   PubMed Web of Science ®Google Scholar
• Baldwin H, Webster G, Stein Gold L, et al. 50 years of topical retinoids for acne: evolution of treatment. Am J Clin Dermatol. 2021;22(3):315–327.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013;12(4):438–446.
   PubMed Web of Science ®Google Scholar
• Bhatia N, Weiss JS, Sadick N, et al. Novel polymeric tazarotene 0.045% lotion for moderate-to-severe acne: pooled phase 3 analysis by race/ethnicity. J Drugs Dermatol. 2020;19(7):727–734.
   PubMed Web of Science ®Google Scholar